Cencora Stock

$289.15

0.53% yesterday

NYSE, Aug 12, 10:00 pm CET

ISIN

US03073E1055

Symbol

COR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health Care Equipment & Services

Industry

Health Care Providers & Services

Overview Dividends Analysts Charts News Strategies

Cencora Stock price

$289.15

+185.60 179.24% 5Y

NYSE, Closing price Tue, Aug 12 2025

-1.55 0.53%

ISIN

US03073E1055

Symbol

COR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health Care Equipment & Services

Industry

Health Care Providers & Services

Key metrics

Basic

Market capitalization

$56.4b

Enterprise Value

$62.4b

Net debt

$6.0b

Cash

$2.2b

Shares outstanding

193.9m

Valuation (TTM | estimate)

P/E

29.9 | 18.2

P/S

0.2 | 0.2

EV/Sales

0.2 | 0.2

EV/FCF

54.6

P/B

28.5

Dividends

DPS

$2.20

Yield 1Y | 5Y

0.8% | 1.1%

Growth 1Y | 5Y

7.8% | 5.8%

Payout 1Y | 3Y

27.1% | 24.2%

Increased

20 Years

Financials (TTM | estimate)

Revenue

$316.7b | $324.8b

EBITDA

$4.5b | $4.8b

EBIT

$3.5b | $4.2b

Net Income

$1.9b | $3.1b

Free Cash Flow

$1.1b

Growth (TTM | estimate)

Revenue

11.6% | 10.5%

EBITDA

13.4% | 15.8%

EBIT

19.2% | 39.3%

Net Income

2.2% | 105.1%

Free Cash Flow

-70.2%

Financial Health

Equity Ratio

1.0%

Return on Equity

233.6%

ROCE

17.3%

ROIC

Debt/Equity

4.2

EPS

$9.7

FCF per Share

$5.9

Short interest

6.3%

Employees

44k

Rev per Employee

$6.7m

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Cencora Stock Analysis

Unlock Scores for Free

??

22 Analysts have issued a Cencora forecast:

15x Buy

68%

7x Hold

32%

More details on Analyst Estimates Including Price Targets

22 Analysts have issued a Cencora forecast:

Buy

68%

Hold

32%

Analyst Estimates with Stock Price Targets

Financial data from Cencora

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	316,654 316,654	12% 12% 100%
- Direct Costs	305,884 305,884	12% 12% 97%
Gross Profit	10,771 10,771	13% 13% 3%
- Selling and Administrative Expenses	6,235 6,235	12% 12% 2%
- Research and Development Expense	- -	- -
EBITDA	4,535 4,535	13% 13% 1%
- Depreciation and Amortization	1,069 1,069	2% 2% 0%
EBIT (Operating Income) EBIT	3,466 3,466	19% 19% 1%
Net Profit	1,897 1,897	2% 2% 1%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cencora Stock News

Positive

Seeking Alpha

●

about 8 hours ago

Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap

Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x forward P/E, well above the 5-year average, making the risk/reward unattractive at current levels. Key risks include heavy revenue exposure to Walgreens Boots Alliance, which faces solvency issues and...

Positive

Seeking Alpha

●

4 days ago

Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy

I initiate Cencora, Inc. with a Buy rating and a fair value of $337, due to its stable business model and strategic specialty drug expansion. Cencora's acquisition of Retina Consultants of America and focus on GLP-1 drugs strengthen its specialty solutions, supporting long-term growth and margin improvement. Management's commitment to digital infrastructure and specialty expertise positions Cen...

Neutral

Seeking Alpha

●

6 days ago

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Cencora, Inc. (NYSE:COR ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.

More Cencora News

Company Profile

AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.

Head office	United States
CEO	Robert Mauch
Employees	44,000
Founded	1947
Website	www.cencora.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now